Lilly Extends Lead in Obesity Treatments as Rivals Surface New Data
Eli Lilly reinforced its frontrunner position in the expanding obesity treatment market after releasing detailed trial data for its once-weekly injection retatrutide, which investors and clinicians view as likely to deliver the largest weight losses among current and pipeline therapies. A raft of presentations at a major diabetes meeting from Roche…